Greater Bay Area Sub-center for Drug Evaluation and Medical Device Evaluation and Inspection of National Medical Products Administration

In January 2020, the SCOPSR approved establishment of the Greater Bay Area Sub-center for Drug Evaluation and Medical Device Evaluation and Inspection of National Medical Products Administration. The main provincial and municipal leaders promoted this entity with high profile. The two sub-centers were officially registered at the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone on December 23, 2020. The initial office is at F11 and F13, Block G, Shenzhen-Hong Kong International Science and Technology Park, but it will be relocated to the Shenzhen-Hong Kong Open Innovation Center in the future.

The two sub-centers are responsible for assisting Medical Products Evaluation Center of National Medical Products Administration and Center of Medical Device Evaluation Center of National Medical Products Administration in communication and guidance and the inspections. In the future, they will also serve the biomedicine enterprises and innovation teams in Guangdong-Hong Kong-Macao Greater Bay Area and provide technical guidance of national-level teams. They will establish the working mechanism comprised of dedicated personnel, proactive interfacing and whole-process guidance, adequately utilize the industrial foundation of Shenzhen, Hong Kong and Macao and the advantages of China Unicom (Hong Kong) in international innovation resources and international market, attract the international top-notch talents and technologies, and enhance the global competitive power of China in biomedicines and medical devices.